Antitrust fine of 6 million to Dr Automobiles: cars indicated as Italian but produced in China

Antitrust fine of 6 million to Dr Automobiles: cars indicated as Italian but produced in China
Antitrust fine of 6 million to Dr Automobiles: cars indicated as Italian but produced in China

Economy

According to the Authority, the two companies implemented unfair commercial practices

1′ reading

Fine of 6 million euros for Dr Automobiles and its subsidiary Dr Service & Parts. The Competition and Market Authority decided this, deeming that the two companies had implemented two unfair commercial practices. in particular, the Antitrust «has ascertained that Dr Automobiles, in the context of the messages and/or commercial communications disseminated at least starting from December 2021 through various channels, has indicated Italy as the origin and place of actual production of the cars marketed with the Dr and Evo brands. However, these are vehicles produced in China, except for marginal finishing and completion interventions” in our country. For the Authority, “the deceptive practice coincided with a period of strong increase in sales of Dr and Evo branded cars on the Italian market”.

Furthermore, the investigation ascertained that «Dr Service & Parts and Dr Automobiles, at least starting from 2022, did not guarantee an adequate supply of spare parts nor correct after-sales assistance, through the dealer network and/or of authorized workshops, which – among other things – were not provided with suitable technical training”. For the Authority, “this practice can hinder the exercise of consumer rights, including the right to obtain car repairs and adequate after-sales assistance, also within the scope of the legal guarantee of conformity of the purchased product” .

(Il Sole 24 Ore Radiocor)

View on ilsole24ore.com

 
For Latest Updates Follow us on Google News
 

PREV Today’s stock markets, June 20th. The EU closes in recovery. ECB: “No commitment on rates”. Switzerland cuts them by surprise. Beijing is studying the purchase of securities
NEXT Bonds, between divergences on rates and macro risks, an investment grade opportunity arises